Clinical trials: Metastatic Head and Neck Cancer
Recurrent Head and Neck Cancer, Head and Neck Cancer
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer.
- Conditions
- Recurrent Head and Neck Cancer, Head and Neck Cancer, Head and Neck Neoplasms, Metastatic Cancer
- Trial name
- NCT03691714
- Testing
- Durvalumab, Cetuximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Cincinnati
Head and Neck Carcinoma, Adenocarcinoma
A Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
This is a non-randomized, phase II, open label study of anlotinib hydrochloride capsules in recurrent/metastatic adenocarcinomas of head and neck. The primary purpose of this study is to evaluate the efficacy of anlotinib.
- Conditions
- Head and Neck Carcinoma, Adenocarcinoma, Recurrent Disease, Distantly Metastatic Malignant Neoplasm
- Trial name
- NCT03591666
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Head and Neck Squamous Carcinoma
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is an important disease with the incidence of 6th all over the world. In Taiwan it is the fifth of male cancer mortality.
- Trial name
- NCT04361409
- Testing
- Rituximab, Cisplatin, Gemcitabine
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- China Medical University Hospital
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Breast Cancer, Colorectal Cancer
Family Quality of Life Among Families With a Member Who is a Cancer Patient
RATIONALE: Developing a questionnaire that can be used to assess the quality of life among people who have a family member with cancer may help the study of cancer in the future.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00544336
- Testing
- questionnaire administration, survey administration, quality-of-life assessment
- Where
- 3 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Squamous Cell Carcinoma, Oncolytic Virus
H101 Plus TACE for r/m HNSCC
This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE
- Trial name
- NCT07398664
- Testing
- H101, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- West China Hospital
Squamous Cell Carcinoma of the Head and Neck
Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck
Primary To investigate in patients with relapsed or metastatic squamous cell carcinoma of the head and neck whether progression free survival (PFS) in the arm with cetuximab, paclitaxel and carboplatin based chemotherapy is not…
- Trial name
- CETMET (NCT01830556)
- Testing
- Cetuximab
- Where
- 5 sites in Denmark, Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska University Hospital
Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer
Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.
- Conditions
- Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT06251973
- Testing
- AgenT-797, Botensilimab, Balstilimab
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Oral Mucositis
Study of Dentoxol® Mouthrinse for Oral Mucositis
The primary objective of this study is to determine the efficacy of Dentoxol® mouthrinse in reducing the severity of oral mucositis secondary to radiation therapy for head and neck cancer.
- Trial name
- NCT02885376
- Testing
- Dentoxol
- Where
- 3 sites in Chile
- Volunteers
- 108 people
- Sponsor
- Ingalfarma SpA
Lymphedema, Lymphedema of Face
A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema
To compare the effectiveness of an APCD to Usual Care in the management of lymphedema and fibrosis (LEF) in head and neck cancer (HNC) survivors.
- Conditions
- Lymphedema, Lymphedema of Face, Lymphedema, Secondary, Lymphedema Due to Radiation
- Trial name
- NCT04797390
- Testing
- Advanced Pneumatic Compression Device (APCD), Usual Care
- Where
- 10 sites in United States
- Volunteers
- 236 people
- Sponsor
- Tactile Medical
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Esophageal Cancer, Gastric Cancer
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients who have locally…
- Trial name
- NCT00005876
- Testing
- rubitecan
- Where
- United States
- Sponsor
- Astex Pharmaceuticals, Inc.
Esophageal Neoplasm
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
In patients with esophageal cancer, treatment with curative intent can be given to medically fit patients without distant metastases. It may consist of chemoradiotherapy or surgery alone or in combination.
- Trial name
- LERFOX-C (NCT02636088)
- Testing
- Cetuximab
- Volunteers
- 51 people
- Sponsor
- Gabriella Alexandersson von Döbeln
Thyroid Cancer
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with…
- Trial name
- NCT00124527
- Testing
- Irofulven + capecitabine
- Where
- 10 sites in United States, Argentina and 4 more
- Volunteers
- 35 people
- Sponsor
- Eisai Inc.
Carcinoma of Unknown Primary, Head and Neck Cancer
PET Scans and CT Scans in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Imaging procedures, such as PET scan and CT scan, may help doctors predict a patient's response to treatment and plan the best treatment.
- Trial name
- NCT00388024
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Wake Forest University Health Sciences
Nasopharyngeal Carcinoma
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
Hypothesis We hypothesise that intermittent dosing of the anti-angiogenic RTKI sunitinib or bevacizumab prior to systemic cisplatin and gemcitabine chemotherapy to transiently "normalise" tumour vasculature in patients with…
- Trial name
- NCT01309633
- Testing
- 12.5mg sunitinib with Cisplatin and Gemcitabine, 25mg Sunitinib alternating with Cisplatin and Gemcitabine, 7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic
NR in Chemo-induced Peripheral Neuropathy
The purpose of this single-arm phase II trial is to determine whether nicotinamide riboside (NIAGEN®) prevents the progression of peripheral sensory neuropathy in patients receiving infusions of paclitaxel or nab-paclitaxel for…
- Conditions
- Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV
- Trial name
- NCT03642990
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Donna Hammond, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.